The shares of Sorrento Therapeutics, Inc. have increased by more than 117.11% this year alone. The shares recently went up by 13.79% or $1 and now trades at $8.25. The shares of Sabre Corporation (NASDAQ:SABR), has jumped by 5.22% year to date as of 02/14/2018. The shares currently trade at $21.57 and have been able to report a change of 11.30% over the past one week.
The stock of Sorrento Therapeutics, Inc. and Sabre Corporation were two of the most active stocks on Wednesday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.
Next 5Y EPS Growth: 37.00% versus 4.51%
When a company is able to grow consistently in terms of earnings at a high compound rate have the highest likelihood of creating value for its shareholders over time. Analysts have predicted that SRNE will grow it’s earning at a 37.00% annual rate in the next 5 years. This is in contrast to SABR which will have a positive growth at a 4.51% annual rate. This means that the higher growth rate of SRNE implies a greater potential for capital appreciation over the years.
Profitability and Returns
Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. SRNE has an EBITDA margin of 61.72%, this implies that the underlying business of SRNE is more profitable. The ROI of SRNE is -75.50% while that of SABR is 9.10%. These figures suggest that SABR ventures generate a higher ROI than that of SRNE.
The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, SRNE’s free cash flow per share is a negative -0.2, while that of SABR is positive 1.87.
Liquidity and Financial Risk
The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for SRNE is 0.50 and that of SABR is 0.90. This implies that it is easier for SRNE to cover its immediate obligations over the next 12 months than SABR. The debt ratio of SRNE is 0.21 compared to 5.41 for SABR. SABR can be able to settle its long-term debts and thus is a lower financial risk than SRNE.
SRNE currently trades at a P/B of 4.85, and a P/S of 5.01 while SABR trades at a forward P/E of 15.97, a P/B of 9.34, and a P/S of 1.66. This means that looking at the earnings, book values and sales basis, SRNE is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.
Analyst Price Targets and Opinions
The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of SRNE is currently at a -57.69% to its one-year price target of 19.50. Looking at its rival pricing, SABR is at a -4.56% relative to its price target of 22.60. This figure implies that over the next one year, SABR is a better investment.
When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), SRNE is given a 1.50 while 2.40 placed for SABR. This means that analysts are more bullish on the outlook for SABR stocks.
Insider Activity and Investor Sentiment
Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for SRNE is 1.50 while that of SABR is just 11.26. This means that analysts are more bullish on the forecast for SRNE stock.
The stock of Sabre Corporation defeats that of Sorrento Therapeutics, Inc. when the two are compared, with SABR taking 6 out of the total factors that were been considered. SABR happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, SABR is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for SABR is better on when it is viewed on short interest.